Department of Medicine, Rheumatology Unit, Karolinska Institutet, S-171 76 Stockholm, Sweden.
J Biol Chem. 2010 Sep 17;285(38):29254-61. doi: 10.1074/jbc.M110.114454. Epub 2010 Jul 6.
Microsomal prostaglandin E synthase-1 (MPGES1) is induced during an inflammatory reaction from low basal levels by pro-inflammatory cytokines and subsequently involved in the production of the important mediator of inflammation, prostaglandin E(2). Nonsteroidal anti-inflammatory drugs prevent prostaglandin E(2) production by inhibiting the upstream enzymes cyclooxygenases 1 and 2. In contrast to these conventional drugs, a new generation of NSAIDs targets the terminal enzyme MPGES1. Some of these compounds potently inhibit human MPGES1 but do not have an effect on the rat orthologue. We investigated this interspecies difference in a rat/human chimeric form of the enzyme as well as in several mutants and identified key residues Thr-131, Leu-135, and Ala-138 in human MPGES1, which play a crucial role as gate keepers for the active site of MPGES1. These residues are situated in transmembrane helix 4, lining the entrance to the cleft between two subunits in the protein trimer, and regulate access of the inhibitor in the rat enzyme. Exchange toward the human residues in rat MPGES1 was accompanied with a gain of inhibitor activity, whereas exchange in human MPGES1 toward the residues found in rat abrogated inhibitor activity. Our data give evidence for the location of the active site at the interface between subunits in the homotrimeric enzyme and suggest a model of how the natural substrate PGH(2), or competitive inhibitors of MPGES1, enter the active site via the phospholipid bilayer of the membrane.
微粒体前列腺素 E 合酶-1(MPGES1)在炎症反应中由促炎细胞因子从低基础水平诱导产生,随后参与产生炎症的重要介质前列腺素 E2(PGE2)。非甾体抗炎药通过抑制上游酶环氧化酶 1 和 2 来预防 PGE2 的产生。与这些传统药物不同,新一代的 NSAIDs 以终末酶 MPGES1 为靶点。其中一些化合物对人 MPGES1 具有很强的抑制作用,但对大鼠同源物没有作用。我们在酶的大鼠/人嵌合形式以及几种突变体中研究了这种种间差异,并鉴定出人 MPGES1 中的关键残基 Thr-131、Leu-135 和 Ala-138,它们作为 MPGES1 活性位点的守门员起着至关重要的作用。这些残基位于跨膜螺旋 4 中,位于蛋白质三聚体中两个亚基之间的裂隙入口处,调节大鼠酶中抑制剂的进入。在大鼠 MPGES1 中向人残基的交换伴随着抑制剂活性的增加,而在人 MPGES1 中向大鼠中发现的残基的交换则消除了抑制剂的活性。我们的数据为活性位点位于同三聚体酶亚基之间界面的位置提供了证据,并提出了一种模型,说明天然底物 PGH2 或 MPGES1 的竞争性抑制剂如何通过膜的磷脂双层进入活性位点。